about
Tobramycin Inhalation Powder (TIP): An Efficient Treatment Strategy for the Management of Chronic Pseudomonas Aeruginosa Infection in Cystic FibrosisNebulized antibiotics for ventilator-associated pneumonia: a systematic review and meta-analysisInhaled Antibiotics for Gram-Negative Respiratory InfectionsInhaled antibiotics for lower airway infections.Optimal airway antimicrobial therapy for cystic fibrosis: the role of inhaled aztreonam lysine.Aztreonam lysine: a novel inhalational antibiotic for cystic fibrosis.Inhaled antibiotics for gram-negative respiratory infections.Tobramycin Inhalation Powder™: a novel drug delivery system for treating chronic Pseudomonas aeruginosa infection in cystic fibrosis.Aztreonam (for inhalation solution) for the treatment of chronic lung infections in patients with cystic fibrosis: an evidence-based review.Delivering antibiotics to the lungs of patients with ventilator-associated pneumonia: an update.Inhaled aztreonam lysine: an evidence-based review.Tobramycin inhalation powder: an efficient and efficacious therapy for the treatment of Pseudomonas aeruginosa infection in cystic fibrosis.Tobramycin inhalation powder (TOBI Podhaler) for the treatment of lung infection in patients with cystic fibrosis.Polymer assisted entrapment of netilmicin in PLGA nanoparticles for sustained antibacterial activity.Aerosolized antibiotics in cystic fibrosis: current and future trends.Inhaled Antimicrobials for Ventilator-Associated Pneumonia: Practical Aspects.Clinical application analysis of andrographolide total ester sulfonate injection, a traditional Chinese medicine licensed in China.Aerosolized recombinant human lysozyme enhances the bactericidal effect of tobramycin in a hamster model of Pseudomonas aeruginosa-induced pneumonia.
P2860
Q26829604-5B6A7A9C-10EB-49AD-85B0-161816C304BDQ28084615-048F2166-ED04-452D-BDB7-B43108532985Q28386160-3CF76DAE-3C6D-4FEC-A474-20A8F1DCD85DQ33640488-96A08CB5-DFFE-4A92-B00E-6CC8C921DB26Q37738904-97210DCE-A001-4ADC-B7A9-325C3F62073CQ37775620-29B0C066-0A36-44DD-AAC3-36720B238D7CQ37937558-F50B4CEE-453F-490E-ABC8-4A3EB95F3967Q37940005-6A71A9B6-9416-4D60-966D-551FF516F2E5Q37948797-91BEBB29-70CC-4BF8-9264-6EAB23FD518FQ38102781-420C3D9E-90EB-47EF-B733-24F497347766Q38132897-202AB400-89AC-4C05-8F02-C47EFB0902B8Q38358856-E4FB30AD-2DE2-4C97-82D1-85D1959B6840Q38630919-1B3B0489-F898-422D-8106-7F7541455F12Q38955018-0A588002-39FD-40B1-AA71-1168F9BA7A89Q40065026-D18E4BFF-E3F7-46A9-B9A2-12FEC3CB3AFDQ40121090-DC6AAA6A-C81C-427D-AA9A-381DB8276895Q40248931-2CA45D5B-34E1-4AA1-BE46-55A4B6155764Q51764788-08395118-4226-4FE1-A0A7-615941C2ACAE
P2860
description
2001 nî lūn-bûn
@nan
2001 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Formulation of aerosolized therapeutics.
@ast
Formulation of aerosolized therapeutics.
@en
Formulation of aerosolized therapeutics.
@nl
type
label
Formulation of aerosolized therapeutics.
@ast
Formulation of aerosolized therapeutics.
@en
Formulation of aerosolized therapeutics.
@nl
prefLabel
Formulation of aerosolized therapeutics.
@ast
Formulation of aerosolized therapeutics.
@en
Formulation of aerosolized therapeutics.
@nl
P1433
P1476
Formulation of aerosolized therapeutics.
@en
P2093
P304
P356
10.1378/CHEST.120.3_SUPPL.94S
P407
P433
P577
2001-09-01T00:00:00Z